atazanavir teva 300 mg kapsel, hård
teva sweden ab - atazanavirsulfat - kapsel, hård - 300 mg - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; atazanavirsulfat 341,744 mg aktiv substans
atazanavir teva 150 mg kapsel, hård
teva sweden ab - atazanavirsulfat - kapsel, hård - 150 mg - propylenglykol hjälpämne; laktosmonohydrat hjälpämne; atazanavirsulfat 170,872 mg aktiv substans
curosurf 80 mg/ml instillationsvätska för luftvägarna, suspension
orifarm ab - porcina lunglipider och protein - instillationsvätska för luftvägarna, suspension - 80 mg/ml - porcina lunglipider och protein 80 mg aktiv substans
curosurf 80 mg/ml instillationsvätska för luftvägarna, suspension
paranova läkemedel ab - porcina lunglipider och protein - instillationsvätska för luftvägarna, suspension - 80 mg/ml - porcina lunglipider och protein 80 mg aktiv substans
micafungin bioglan 100 mg pulver till koncentrat till infusionsvätska, lösning
bioglan ab - mikafunginnatrium - pulver till koncentrat till infusionsvätska, lösning - 100 mg - laktosmonohydrat hjälpämne; mikafunginnatrium 101,72 mg aktiv substans
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiska medel - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiska medel - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib avansor 50 mg kapsel, hård
avansor pharma oy - sunitinibmalat - kapsel, hård - 50 mg - sunitinibmalat 66,83 mg aktiv substans
sunitinib avansor 12,5 mg kapsel, hård
avansor pharma oy - sunitinibmalat - kapsel, hård - 12,5 mg - sunitinibmalat 16,71 mg aktiv substans
sunitinib avansor 25 mg kapsel, hård
avansor pharma oy - sunitinibmalat - kapsel, hård - 25 mg - sunitinibmalat 33,41 mg aktiv substans